Illumina Inc. reported full year (FY) 2025 consolidated revenue of USD 4.38 billion. Shipments to customers outside the United States accounted for USD 2.10 billion, representing 48 percent of total consolidated revenue in 2025. The company operates with one reportable segment, Core Illumina, following the spin-off of GRAIL into a separate publicly traded company on June 24, 2024. Illumina continues to focus on innovation in DNA sequencing and array-based technologies, serving research, clinical, and applied markets. Its products are utilized in life sciences, oncology, reproductive health, agriculture, and other emerging applications. The management highlighted ongoing efforts to scale the organization and infrastructure, aiming to demonstrate superior throughput, cost, and accuracy for its product portfolio. The company noted that macroeconomic factors such as inflation, exchange rate fluctuations, and global economic uncertainty remain areas of focus for its operational outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001110803-26-000024), on February 12, 2026, and is solely responsible for the information contained therein.